Enzo Biochem (ENZ) Aktie Kurs
Enzo Biochem Kurs
De seneste 19 år voksede Enzo Biochems omsætning med 18,4 % årligt og nåede 992,90 Mio. USD. Indtjening pr. aktie er faldet med 30,0 % om året de seneste 5 år. For Enzo Biochem er nettoavance på -0,8 % ned i forhold til 6,7 % for et par år siden. Ved dagens kurs bliver direkteafkastet cirka 18,20 %.
Enzo Biochem aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Enzo Biochem aktie og aktieanalyse
Hyppigt stillede spørgsmål om Enzo Biochem-aktien
Enzo Biochem Inc is a life sciences and biotechnology company. Its business model encompasses the development, manufacturing, and commercialization of innovative diagnostic and research products. The company offers a diverse range of products and services catering to the life sciences industry. These include molecular diagnostics, immunohistochemistry, flow cytometry, and drug discovery research tools. Enzo Biochem Inc also operates clinical reference laboratories that provide a wide array of testing services. By leveraging its proprietary technology platforms, the company aims to facilitate advancements in personalized medicine and scientific research. Through collaborations and strategic partnerships, Enzo Biochem Inc strives to contribute to advancements in healthcare and improve patient outcomes.
Enzo Biochem Inc is primarily active in the life sciences and biotechnology industry.
The main competitors of Enzo Biochem Inc in the market include companies such as Thermo Fisher Scientific, Quidel Corporation, and Bio-Rad Laboratories.
Enzo Biochem Inc, founded in 1976, is a leading life sciences and biotechnology company based in New York. It specializes in the development, production, and commercialization of innovative diagnostic and research products worldwide. Enzo Biochem is known for its cutting-edge technology platforms, including gene regulation, therapeutics, and molecular diagnostic systems. The company's focus extends to areas such as biomarkers, infectious diseases, and cancer diagnostics. With a strong history of innovation and a commitment to delivering high-quality products and services, Enzo Biochem continues to play a significant role in advancing the field of life sciences and improving patient care.
Enzo Biochem Inc has achieved several significant milestones throughout its history. In 1976, the company was founded by Dr. Elazar Rabbani and developed innovative technologies for the life sciences and biotechnology sectors. In 1985, Enzo introduced the first commercial oligo synthesizer, revolutionizing DNA research. The company continued to expand its portfolio and in the late 1990s, launched diagnostic products for molecular oncology and genetics. Enzo has also successfully obtained numerous patents for its inventions. Over the years, Enzo Biochem Inc has established itself as a leading player in the life sciences industry with its strong commitment to innovation, research, and development.
Enzo Biochem Inc is primarily present in the United States.
Enzo Biochem Inc represents the values of innovation, excellence, and integrity. The company is committed to advancing scientific research and delivering cutting-edge diagnostic and therapeutic solutions. Enzo Biochem Inc embraces a corporate philosophy centered around quality, accuracy, and collaboration. They strive to provide accurate and reliable products and services to enable healthcare professionals to improve patient outcomes. With a strong focus on research and development, Enzo Biochem Inc aims to address significant unmet medical needs and drive advancements in the field of life sciences.
5 analytikere vurderer i øjeblikket Enzo Biochem-aktien: 4 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at Enzo Biochem genererer omsætning på 107,03 Mio. USD og indtjening pr. aktie på -0,07 USD.
Omregnet til den aktuelle valutakurs handles Enzo Biochem-aktien til 0,49 EUR (0,55 USD).
Enzo Biochem-aktien (ENZ) er noteret på 6 børser, herunder: NYSE (ENZ), London (0IHV.L), SIX (Zürich) (EZB.SW), Frankfurt (EZB.F), München (EZB.MU), Düsseldorf (EZB.DU).
Enzo Biochem Inc is a leading company in the field of life science research, offering a wide range of products and services. The company operates in three main business areas: life sciences, clinical labs, and therapeutics. In the life sciences field, the company provides researchers with a comprehensive range of products and services to better understand the fundamentals of life, including enzymes and proteins, genetic engineering, and immunology. In the clinical lab services area, Enzo Biochem Inc offers specialized testing procedures and preparation technologies to its customers, operating multiple clinical labs in New York and New Jersey. The company also develops a wide range of therapeutics for the treatment of diseases and disorders, based on genetic and biochemical technologies to understand disease mechanisms and develop more effective treatment methods. Enzo Biochem Inc places a strong emphasis on innovation, continuously investing in research and development to provide customers with value-added technologies and methods. Additionally, the company is committed to sustainability and environmental friendliness, developing technologies and products that meet customer requirements while minimizing environmental impact. Overall, Enzo Biochem Inc provides customers with a comprehensive range of products and services to address the challenges of life science research and development, with a focus on innovation and customer satisfaction.
forventet-omsætningen for Enzo Biochem er 107,03 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Enzo Biochem er -9,72 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Enzo Biochem er i øjeblikket -7,85. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Enzo Biochem-aktien.
Pris-til-salgs-forholdet (P/S) for Enzo Biochem er i øjeblikket 0,71. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Enzo Biochem-aktien.
AlleAktien-kvalitetsscore for Enzo Biochem er 6/10.
ISIN for Enzo Biochem er US2941001024. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Enzo Biochem er 865607. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Enzo Biochem er ENZ. Tickersymbolet bruges til at handle Enzo Biochem-aktier på børsen.
Enzo Biochem aktie
Enzo Biochem Peer Group
Enzo Biochem Ticker
Enzo Biochem FIGI
Alle fundamentale data om Enzo Biochem i deep dive
Vores aktieanalyse af Enzo Biochem-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Enzo Biochem. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: